GlassScriptPhysician profile
Terri Horan
NPI 1588622922
$4,597.24
in general payments reported to CMS, 2019-2025
24 companies · $554 in 2025
The $554 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $388 · 2021: $358 · 2022: $804 · 2023: $1,134 · 2024: $601 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214 · Education: $74.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.09 |
| Education | $74.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $925.13 | 2020-2025 | Tavneos, Otezla, Repatha |
| Abbvie INC. | $750.31 | 2019-2025 | |
| Abbott Laboratories | $507.34 | 2019-2023 | Octrode |
| Lilly USA, LLC | $320.64 | 2019-2024 | Taltz |
| Teva Pharmaceuticals USA, INC. | $260.74 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $216.23 | 2022-2024 | Saphnelo |
| Medtronic, INC. | $201.88 | 2022-2025 | Inceptiv |
| Si-Bone, INC. | $179.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $177.07 | 2019-2024 | Orencia |
| Janssen Biotech, INC. | $173.39 | 2022-2024 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $154.35 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.31 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $116.24 | 2021 | |
| Cardiovascular Systems INC. | $103.62 | 2019 | |
| Glaxosmithkline, LLC. | $96.17 | 2022-2023 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $89.57 | 2019-2023 | Tymlos |
| Celgene Corporation | $60.68 | 2019 | |
| Ucb, INC. | $32.01 | 2022 | |
| Sobi, INC | $19.25 | 2023 | |
| Horizon Therapeutics Plc | $19.21 | 2022 | |
| Hikma Pharmaceuticals USA | $17.12 | 2020 | |
| Genentech USA, INC. | $17.07 | 2019 | |
| Alfasigma USA, INC. | $15.35 | 2021 | |
| Fresenius Kabi USA, LLC | $14.51 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Horan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.